Search Protocols under revision. Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupIndolent LymphomasDiseaseHairy Cell LeukemiaSubgroupBRAF V600E mutationICD10C91.4-MeSHLeukemia, Hairy CellSequenceCLAD5,6 followed by RITU375, HCL, A (PID865) -|- B (PID866)RITU375/VEMU960 - RITU375, HCL, A (PID1802) -|- B (PID1803)VEMU/OBIN: VEMU960, HCL, C1 (PID2684) -|- C2 (PID2685) -|- C3-4 (PID2686)ChemotherapyChemo-substanceBendamustineCladribineDabrafenibIbrutinibMoxetumomab PasudotoxObinutuzumabPentostatinRituximabTrametinibVemurafenibVenetoclaxZanubrutinibChemo-substanceBendamustineCladribineDabrafenibIbrutinibMoxetumomab PasudotoxObinutuzumabPentostatinRituximabTrametinibVemurafenibVenetoclaxZanubrutinibChemo-substanceBendamustineCladribineDabrafenibIbrutinibMoxetumomab PasudotoxObinutuzumabPentostatinRituximabTrametinibVemurafenibVenetoclaxZanubrutinibChemo-substanceBendamustineCladribineDabrafenibIbrutinibMoxetumomab PasudotoxObinutuzumabPentostatinRituximabTrametinibVemurafenibVenetoclaxZanubrutinibNo. Substances12 RadiotherapySupportive therapySupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPrednisoloneNo. Substances3467Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleThird line Therapy phaseConsolidationInductionReinductionTherapy intentiondisease controlpalliativeRisksAlopeciaAnemia Hb below 8g/dlArthalgiaBleedingCapillary Leak SyndromeCardiotoxicityDiarrheaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaHeadacheHemolytic Uremic SyndromeHepatotoxicityHyperbilirubinemiaHyperglycemiaHypertensionHypocalcemiaHypophosphatemiaIncrease AminotransferasesInfectionsInfusion ReactionLeukopeniaLymphopeniaMyalgiasNeutropeniaPruritusPyrexiaQTc Time ExtensionRashRenal FailureThrombocytopenia below 50 000/µlUpper Respiratory Tract Infection only studiesPublicationAuthorBurotto MElse MGrever MKreitman RKreitman RJKreitman RJ Paul JHRavandiRobak TRogers KA Tam CSThomas DATiacci Evon Rohr ADiseaseHaarzelleukämie, Drittlinie, ECOG 0-2Haarzellleukämie (Varianten), Erst- und ZweitlinieHaarzellleukämie, aktive Erkrankung, ECOG 0-3Haarzellleukämie, BRAF-V600E Mut +, vorbehandelt (z.T. mehrfach)Haarzellleukämie, BRAF-V600E Mutation, refraktär gegen Purinanaloga, oder ein früheres Rezidiv nach PurinanalogaHaarzellleukämie, BRAF V600E-Mutation, rezidiviert, therapierefraktär, mind. 2 Vortherapien, ECOG 0-2Haarzellleukämie, Erstlinie, ECOG 0-2Haarzellleukämie, klassische, ErstlinieHaarzellleukämie, klassische und varianteHaarzellleukämie, rezidiviert, therapierefraktär, ECOG 0-2Haarzellleukämie, therapieresistent oder rezidiviertHaarzellleukämie, therapieresistent oder rezidiviert.Haarzellleukämie, Zweitlinie nach Nukleosidanalogon, ECOG 0-2Haarzellleukämie Erstdiagnose oder Rezidiv nach nicht Cladribin-haltiger Vortherapie, ECOG 0-2Haarzellleukämie Erstlinie, ECOG 0-3refraktäre oder rezidivierende HCL nach Pentostatin oder CladribintherapieOriginDepartment of Hematology, Medical University of Lodz, PALGDepartment of Leukemia and Hematopathology, University of Texas, MD Anderson Cancer Center, USAInstitute of Hematology, Ospedale Santa Maria della Misericordia, University of Perugia, Italy, HCL-PG03Institute of Hematology – CREO, Ospedale Santa Maria della Misericordia, University of Perugia, ItalyLaboratory of Molecular Biology, Clinical Center, Bethesda, MarylandMemorial Sloan Kettering Cancer Center, New YorkNational Cancer Institute, National Institutes of Health, Bethesda, Maryland, USANational Cancer Institute, NIH, Bethesda, MarylandNational Institutes of Health, BethesdaOncology Center, Klinik Hirslanden, Zürich, SchweizSection of Haemato-Oncology, Royal Marsden Hospital/Institute of Cancer Research, Sutton, UKThe Alfred Hospital, Monash University, Melbourne, VIC, AustraliaThe National Cancer Institute, Bethesda, USAThe Ohio State University, ColumbusThe University of Texas M. D. Anderson Cancer Center, HoustonUniversity of Perugia, Perugia, ItalyProtocols in Revision 22 protocols foundCladribine 0.12, Hairy Cell Leukemia (PID862 V1.0)Cladribine 0.14, Hairy Cell Leukemia (PID536 V1.0)Cladribine 0.15 / Rituximab 375, classic Hairy Cell Leukemia and variants (PID864 V1.0)Cladribine 5.6 followed by Rituximab 375, Hairy Cell Leukemia, Part A (PID865 V1.0)Cladribine 5.6 followed by Rituximab 375, Hairy Cell Leukemia, Part B (PID866 V1.0)Dabrafenib 150 / Trametinib 2, Hairy Cell Leukemia (PID2679 V1.0)Ibrutinib 420, Hairy Cell Leukemia (PID2683 V1.0)Moxetumomab Pasudotox 0.04, Hairy Cell Leukemia (PID1713 V1.0)Pentostatin 4 / Rituximab 375, Hairy Cell Leukemia (PID839 V1.0)Pentostatin 4, Hairy Cell Leukemia (PID537 V1.0)Rituximab 375 / Bendamustine 90, Hairy Cell Leukemia (PID1712 V1.0)Rituximab 375 / Vemurafenib 960 - Rituximab 375, Hairy Cell Leukemia, Part A (PID1802 V1.0)Rituximab 375 / Vemurafenib 960 - Rituximab 375, Hairy Cell Leukemia, Part B (PID1803 V1.0)Rituximab 375 / Venetoclax 200, Hairy Cell Leukemia, Cycle 1-2 (PID2690 V1.0)Rituximab 375 / Venetoclax 200, Hairy Cell Leukemia, Cycle 3-8 (PID2696 V1.0)Rituximab 375, Hairy Cell Leukemia (PID538 V1.0)Vemurafenib 960 / Obinutuzumab 1000, Hairy Cell Leukemia, Cycle 2 (PID2685 V1.0)Vemurafenib 960 / Obinutuzumab 1000, Hairy Cell Leukemia, Cycle 3-4 (PID2686 V1.0)Vemurafenib 960, Hairy Cell Leukemia (PID539 V1.1)Vemurafenib 960, Hairy Cell Leukemia, Cycle 1 (PID2684 V1.0)Venetoclax 400, Hairy Cell Leukemia (PID2689 V1.0)Zanubrutinib 160, Hairy Cell Leukemia (PID2676 V1.0)
